PerkinElmer, Inc. (PKI)

Market Growth Driven by Increasing Demand for Real-World Evidence in Drug Development, Rising Focus on Value-Based Healthcare, Growing Cancer Incidence Globally, and Advancements in Data Analytics and AI Technologies REDDING, Calif., May 27, 2025 /PRNewswire/ -- According to a new market research report titled 'RWE Oncology Solutions Market by Component (Datasets, Consulting Services), Application (Drug Development & Approvals, Market Access & Reimbursement/Coverage Decisions, Medical Device Development & Approvals, Post-market Surveillance), End User, and Geography - Global Forecast to 2035', the RWE oncology solutions market is projected to reach $3.51 billion by 2035, up from an estimated $893 million in 2025, growing at a CAGR of 14.7% during the forecast period. The growth of this market is mainly driven by increasing demand for real-world evidence in drug development, rising focus on value-based healthcare, growing cancer incidence and prevalence globally, regulatory support for RWE in healthcare decision-making, and advancements in data analytics and AI technologies. For more comprehensive insights, download the FREE report sample: https://www.meticulousresearch.com/download-sample-report/cp_id=5276 Key Market Drivers and Trends The RWE oncology solutions market is witnessing strong growth, primarily driven by the shift towards patient-centric healthcare models and the adoption of cloud-based RWE platforms that are reshaping traditional evidence generation approaches. Integration of genomic and molecular data with real-time data collection and analysis is gaining momentum. Market expansion is further supported by the growing integration with precision medicine initiatives and the development of AI-powered analytics solutions, especially in developed markets with advanced healthcare infrastructure across pharmaceutical, regulatory, and healthcare provider domains. Latest trends in the RWE oncology solutions market include the development of comprehensive cancer datasets across the healthcare ecosystem and the industry's increasing focus on evidence-driven cancer care solutions. The market is increasingly focusing on robust, integrated platforms that merge comprehensive oncology datasets with advanced analytics capabilities to meet the demands of the rapidly evolving healthcare landscape. Growth Opportunities The market presents substantial growth opportunities in expansion in emerging markets, which offers substantial opportunities for market players looking to reach new customer bases. Another major opportunity lies in the integration with precision medicine initiatives, which enhances the accessibility of personalized cancer care. Additionally, the development of AI-powered analytics solutions and partnerships between healthcare stakeholders are generating new revenue streams for solution providers as organizations increasingly seek evidence-based alternatives to traditional healthcare decision-making methods. Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) – https://www.meticulousresearch.com/product/rwe-oncology-market-5276 Market Challenges Despite significant growth potential, the overall RWE oncology solutions market faces challenges including data privacy and security concerns straining implementation budgets, particularly in cost-sensitive healthcare sectors. Limited interoperability between healthcare systems is creating integration barriers. Additionally, recent global disruptions have exposed vulnerabilities in data standardization processes, affecting data quality and completeness. Rapidly evolving regulatory compliance requirements across different regions are creating implementation concerns, and high implementation and maintenance costs, especially for comprehensive RWE platforms, are delaying adoption, limiting scalability in key healthcare markets. Segment Insights The global RWE oncology solutions market is segmented by component (Datasets [Disparate Datasets, Integrated Datasets], Consulting Services), application (Drug Development & Approvals, Market Access & Reimbursement/Coverage Decisions, Medical Device Development & Approvals, Post-market Surveillance, Other Applications), end user (Pharmaceutical, Biotechnology, and Medical Device Companies, Healthcare Payers, Healthcare Providers, Other End Users), and geography (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa). Market by Component The Datasets segment is expected to account for the largest share of the overall RWE oncology solutions market in 2025, primarily driven by increasing demand for comprehensive cancer data across the healthcare ecosystem, including disparate datasets (EMR/EHR/clinical data, claims & billing data, pharmacy data, cancer registries) and integrated datasets. Their comprehensive coverage, data reliability, and broad adoption across diverse healthcare applications make them indispensable in pharmaceutical research, regulatory submissions, and healthcare decision-making. However, the Consulting Services segment is expected to grow at the fastest rate through 2035, fueled by the growing need for expertise in RWE study design, regulatory guidance, and data interpretation services. Request a customized research analysis tailored to your specific requirements: https://www.meticulousresearch.com/request-customization/cp_id=5276 Market by End User The Pharmaceutical, Biotechnology, and Medical Device Companies segment is expected to account for the largest share of the global RWE oncology solutions market in 2025, primarily due to their substantial investment in oncology R&D, regulatory requirements for post-market surveillance, and the essential requirement for real-world evidence capable of supporting drug development and regulatory submissions. However, the Healthcare Payers segment is expected to witness the highest growth rate during the forecast period, driven by increasing adoption of value-based care models, the need for cost-effectiveness evidence in coverage decisions, and increasing reliance on RWE for value-based healthcare decisions. Geographic Market Insights In 2025, North America is expected to hold the largest share of the global RWE oncology solutions market, followed by Europe, due to its advanced healthcare infrastructure, strong regulatory support for RWE, well-established pharmaceutical industry, favorable reimbursement policies, and the strong presence of prominent RWE solution providers. Additionally, high cancer incidence rates and mature data analytics capabilities contribute significantly to market dominance. However, the Asia-Pacific region, particularly China, India, and South Korea, is projected to experience the fastest growth during the forecast period. This acceleration is mainly driven by rising cancer burden, expanding healthcare infrastructure, growing pharmaceutical investments, increasing awareness about precision medicine approaches, and the region's pivotal role as a global pharmaceutical manufacturing center. Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More)- https://www.meticulousresearch.com/view-pricing/590 Competitive Landscape The global RWE oncology solutions market is characterized by a competitive and dynamic landscape, comprising established healthcare data analytics companies, pharmaceutical service providers, technology giants, and specialized oncology data solution providers, each adopting unique approaches to advancing RWE capabilities. Market evolution is increasingly shaped by trends such as data standardization, integration of disparate data sources, and the development of AI-powered analytics solutions designed to address regulatory compliance across different regions. Leading companies are leveraging advanced data analytics capabilities to achieve comprehensive evidence generation without compromising data quality and are incorporating enhanced security measures to meet the demands of sensitive healthcare data systems. Key players in the global RWE oncology solutions market include IQVIA Holdings Inc., Veracyte Inc., Flatiron Health Inc., IBM Corporation, Oracle Corporation, SAS Institute Inc., ICON plc, Parexel International Corporation, Syneos Health Inc., Cognizant Technology Solutions Corporation, UnitedHealth Group Incorporated, Anthem Inc., Clinigen Group plc, PerkinElmer Inc., and Tempus Labs Inc., among others. Related Reports: Real-world Evidence Solutions Market Size, Share, Forecast, & Trends Analysis by Component (Datasets [Clinical, Claims, Pharmacy], Services) Application (Market Access, Drug Development & Approvals, PMS), and End User - Global Forecast to 2031https://www.meticulousresearch.com/product/real-world-evidence-solutions-market-4954 Real-world Data (RWD) Market by Source (EMR, Claims, Pharmacy, Disease Registries), Application [Market Access, Drug Development & Approvals (Oncology, Neurology), Post Market Surveillance], End User (Pharma, Payers, Providers) - Global Forecast to 2029https://www.meticulousresearch.com/product/real-world-data-market-5297 Real-world Evidence Analytics Market by Application [Market Access & Reimbursement, Drug Development & Approval (Oncology, Neurology, Cardiovascular), Post Market Surveillance, Medical Device Development], End User (Pharma, Payer, Provider) - Global Forecast to 2029https://www.meticulousresearch.com/product/real-world-evidence-analytics-market-5306 About Meticulous Research® We are a trusted research partner for leading businesses worldwide, empowering Fortune 500 organizations and emerging enterprises with market intelligence designed to drive revenue transformation and strategic growth. Our insights reveal future growth opportunities, equipping clients with a competitive edge through a versatile suite of research solutions—including syndicated reports, custom research, and direct analyst engagement. Each year, we conduct over 300 syndicated studies and manage 60+ consulting engagements across eight major sectors and 20+ geographic markets, all to deliver targeted business insights that help our clients lead in a rapidly evolving global market. With a strong focus on problem-solving for complex business challenges, our research enables organizations to navigate change with assertion, aligning it with strategic pathways for sustainable growth. By identifying innovative and effective solutions, we empower leaders to make impactful decisions that drive operational excellence and fuel innovation. We are committed to crafting insights that enhance business performance and help our clients unlock new revenue opportunities, positioning them for long-term success in the competitive global marketplace. To find out more, visit www.meticulousresearch.com or follow us on LinkedIn. Contact:Mr. Khushal BombeMeticulous Market Research Pvt. Ltd.1267 Willis St, Ste 200 Redding,California, 96001, U.S.USA: +1-646-781-8004Europe: +44-203-868-8738APAC: +91 744-7780008Email- [email protected]Visit Our Website: https://www.meticulousresearch.com/Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-researchContent Source: https://www.meticulousresearch.com/product/rwe-oncology-market-5276 Logo: https://mma.prnewswire.com/media/1757980/5251440/Meticulous_Research_Logo_1.jpg

SHELTON, Conn.--(BUSINESS WIRE)--PerkinElmer, a global leader in analytical solutions and specialized services for (bio)pharma, applied and food markets, today announced the acquisition of Project Farma, a subsidiary of Precision for Medicine. Project Farma is a leading life sciences consultancy focused on advancing technical operations from ideation through commercialization, offering project management, project controls, commissioning, qualification and validation, quality compliance and engi.

WISeKey PKI and SEALSQ Post-Quantum Technologies Enhance E-Voting Security through Advanced Cybersecurity and AI Integration

Partnership will expand reach of best-in-class PKI and certificate solutions throughout North America Partnership will expand reach of best-in-class PKI and certificate solutions throughout North America

CALGARY, AB , Aug. 12, 2024 /PRNewswire/ - Parkland Corporation ("Parkland", "we", the "Company", or "our") (TSX: PKI) announced today that it has priced its previously announced private offering of US$500 million of senior unsecured notes due 2032 at an issue price of par. The notes will pay a fixed rate of interest of 6.625% per annum.

CALGARY, AB , Aug. 12, 2024 /PRNewswire/ - Parkland Corporation ("Parkland", "we", the "Company", or "our") (TSX: PKI) announced today that, subject to market and other conditions, it plans to commence a private offering of US$500 million aggregate principal amount of senior unsecured notes due 2032. Parkland intends to use the net proceeds of the offering for the repayment of a portion of the outstanding drawings under its credit facilities.

NEW YORK--(BUSINESS WIRE)--AppViewX, the leader in automated certificate lifecycle management (CLM) and PKI solutions, today announced its AVX ONE Platform has been named a finalist for the US Outstanding Security Performance Awards (OSPAs) 2024. Sponsored by Intel, the OSPAs have teamed up with ASIS International to deliver the ninth edition of the US OSPAs. Winners will be announced September 22nd at the Global Security Exchange (GSX) in Orlando, Florida. Next week AppViewX will be exhibiting, demonstrating the AVX ONE platform and hosting meetings at the Black Hat USA Conference, booth #3027. The AVX ONE Platform is the industry’s most advanced cloud-native certificate lifecycle management (CLM) and PKI solution. It provides unrivaled threat visibility, automation and control of digital certificates to manage machine (non-human) identities in complex hybrid multi-cloud environments. “Being recognized as a finalist for the OSPAs is a testament to the ability of AVX ONE to scale and automate the management all digital identity types across multi-cloud infrastructures for enterprise PKI, IAM, DevSecOps, App, and Network teams,” said Gregory Webb, CEO of AppViewX. “Unlike alternatives, the SaaS-based AVX ONE Platform provides complete visibility and control over all enterprise certificates, while enabling identity-first security and zero trust initiatives.” “The OSPAs provide an important opportunity to recognize and celebrate the work of those dedicated individuals, companies, and teams who deliver outstanding security products and services,” said Professor Martin Gill, Founder of the OSPAs. “This year we have seen our highest number of entries and the judges have had an arduous task in scoring nominations and selecting the finalists. All those that have been chosen represent the very best in the industry and should be very proud.” About AVX ONE Platform As a single unified platform, AVX ONE automatically scales to support digital identity and PKI use cases of all types across hybrid multi-cloud infrastructures for enterprise PKI, IAM, DevSecOps, App, and Network teams, regardless of end customer or MSP deployments. These use cases include Kubernetes and container TLS automation, PKI-as-a-Service (PKIaaS), easy Microsoft PKI modernization, secure code signing, IoT identity security, SSH management, and Post-Quantum Cryptography (PQC) readiness to reduce risk and strengthen security across complex hybrid multi-cloud and edge environments. Deployable on-prem via dedicated cloud or on a mature SaaS platform, AVX ONE runs with a single connector and a single code base. About AppViewX AppViewX is trusted by the world’s leading organizations to reduce risk, ensure compliance, and increase visibility through automated certificate lifecycle management. The AVX One platform provides complete certificate lifecycle management and PKI-as-a-Service using streamlined workflows to prevent outages, reduce security incidents, and enable crypto-agility. Fortune 1000 companies including six of the top ten global commercial banks, five of the top ten global media companies, and five of the top ten managed healthcare providers rely on AppViewX to automate NetOps, SecOps, and DevOps. AppViewX is headquartered in New York with offices in the U.K., Australia, and three development centers of excellence in India. For more information, visit AppViewX and follow us on LinkedIn and X/Twitter.

SHELTON, Conn.--(BUSINESS WIRE)--PerkinElmer, a leading global analytical services and solutions provider, today announced that it has acquired Covaris, a leading developer of solutions to empower life science innovations. The merger will accelerate Covaris' growth potential and expand PerkinElmer's existing life sciences portfolio into the high-growth diagnostics end market. Both companies are majority owned by New Mountain Capital, and terms of the transaction were not disclosed. As precision.

CALGARY, AB, July 14, 2023 /PRNewswire/ – Parkland Corporation (“Parkland”, “we”, the “Company”, or “our”) (TSX: PKI) today announced the appointment of Nora Duke to Parkland’s Board of Directors (the “Board”), effective today. “We are delighted to welcome Nora to our Board of Directors,” said Jim Pantelidis, Chairman of the Board. “Nora brings extensive executive […]...

PerkinElmer (PKI) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $2.41 per share a year ago.

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: PKI), today reported financial results for the first quarter ended April 2, 2023. The Company reported GAAP earnings per share of $4.50, as compared to $1.40 in the same period a year ago. GAAP revenue for the quarter was $675 million, as compared to $963 million in the same period a year ago. GAAP operating income for the quarter was $76 million, as compared to $262 million for the same period a year ago. GAAP operating profit margin was 11.

Revvity (PKI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Revvity's (PKI) first-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.

PerkinElmer (PKI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of PerkinElmer, Inc. (NYSE: PKI) today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 11, 2023 to all shareholders of record at the close of business on July 21, 2023. About The PerkinElmer Life Sciences and Diagnostics Company The PerkinElmer Life Sciences and Diagnostics company – which is to be renamed during the second quarter of 2023 – provides end-to-end solutions that hel.

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer Inc. (NYSE: PKI), today announced that it will release its first quarter 2023 financial results prior to market open on Thursday, May 11, 2023. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.